Babar Ghias's most recent trade in Biocryst Pharmaceuticals Inc. was a trade of 355,050 Emp. Stock Option (Right to Buy) done . Disclosure was reported to the exchange on Dec. 17, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Biocryst Pharma Inc | Babar Ghias | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Dec 2025 | 355,050 | 355,050 | - | - | Emp. Stock Option (Right to Buy) | |
| Biocryst Pharma Inc | Babar Ghias | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Dec 2025 | 121,700 | 268,700 (0%) | 0% | 0 | Common Stock | |
| Biocryst Pharma Inc | Babar Ghias | CFO & Head of Corp Development | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Jul 2025 | 305,000 | 305,000 | - | - | Emp. Stock Option (Right to Buy) | |
| Biocryst Pharma Inc | Babar Ghias | CFO & Head of Corp Development | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Jul 2025 | 147,000 | 147,000 (0%) | 0% | 0 | Common Stock |